top of page
Publications
רשימת פרסומים
1: Dobosz P, Stempor PA, Roszik J, Herman A, Layani A, Berger R, Avni D, Sidi Y,Leibowitz-Amit R. Checkpoint Genes at the Cancer Side of the ImmunologicalSynapse in Bladder Cancer. Transl Oncol. 2019 Dec 20;13(2):193-200. doi:10.1016/j.tranon.2019.10.018. [Epub ahead of print] PubMed PMID: 31869744.2: Percik R, Shlomai G, Tirosh A, Tirosh A, Leibowitz-Amit R, Eshet Y, GreenbergG, Merlinsky A, Barhod E, Steinberg-Silman Y, Sella T. Isolated autoimmuneadrenocorticotropic hormone deficiency: From a rare disease to the dominant causeof adrenal insufficiency related to check point inhibitors. Autoimmun Rev. 2019Dec 12:102454. doi: 10.1016/j.autrev.2019.102454. [Epub ahead of print] Review.PubMed PMID: 31838158.3: Petrylak DP, et al; RANGE study investigators. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma afterplatinum-based therapy (RANGE): overall survival and updated results of arandomised, double-blind, phase 3 trial. Lancet Oncol. 2019 Nov 18. pii:S1470-2045(19)30668-0. doi: 10.1016/S1470-2045(19)30668-0. [Epub ahead of print]PubMed PMID: 31753727.4: Bar J, Markel G, Gottfried T, Percik R, Leibowitz-Amit R, Berger R, Golan T,Daher S, Taliansky A, Dudnik E, Shulman K, Urban D, Onn A. Acute vascular eventsas a possibly related adverse event of immunotherapy: a single-instituteretrospective study. Eur J Cancer. 2019 Oct;120:122-131. doi:10.1016/j.ejca.2019.06.021. Epub 2019 Sep 10. PubMed PMID: 31518968.5: Roszik J, Markovits E, Dobosz P, Layani A, Slabodnik-Kaner K, Baruch EN,Ben-Betzalel G, Grimm E, Berger R, Sidi Y, Schachter J, Shapira-Frommer R, AvniD, Markel G, Leibowitz-Amit R. TNFSF4 (OX40L) expression and survival in locallyadvanced and metastatic melanoma. Cancer Immunol Immunother. 2019Sep;68(9):1493-1500. doi: 10.1007/s00262-019-02382-0. Epub 2019 Sep 9. PubMedPMID: 31501955.6: Motzer RJ, et al; CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019 Oct;20(10):1370-1385.doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Erratum in: Lancet Oncol.2019 Aug 21;:. PubMed PMID: 31427204.7: O'Kane GM, Ezzat S, Joshua AM, Bourdeau I, Leibowitz-Amit R, Olney HJ,Krzyzanowska M, Reuther D, Chin S, Wang L, Brooks K, Hansen AR, Asa SL, Knox JJ.A phase 2 trial of sunitinib in patients with progressive paraganglioma orpheochromocytoma: the SNIPP trial. Br J Cancer. 2019 Jun;120(12):1113-1119. doi:10.1038/s41416-019-0474-x. Epub 2019 May 20. PubMed PMID: 31105270; PubMedCentral PMCID: PMC6738062.8: Leibowitz-Amit R. Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James,et al's Letter to the Editor re: The Case Against the European Medicines Agency'sChange to the Label for Radium-223 for the Treatment of MetastaticCastration-resistant Prostate Cancer. Eur Urol 2019;75:e53. Eur Urol. 2019Jul;76(1):e19. doi: 10.1016/j.eururo.2019.03.013. Epub 2019 Mar 28. PubMed PMID:30928161.9: Gianni M, Qin Y, Wenes G, Bandstra B, Conley AP, Subbiah V, Leibowitz-Amit R,Ekmekcioglu S, Grimm EA, Roszik J. High-Throughput Architecture for DiscoveringCombination Cancer Therapeutics. JCO Clin Cancer Inform. 2018 Dec;2:1-12. doi:10.1200/CCI.17.00054. PubMed PMID: 30652536; PubMed Central PMCID: PMC6873994.10: Hammer L, Laufer M, Dotan Z, Leibowitz-Amit R, Berger R, Felder S, Weiss I,Lawrence YR, Symon Z. Accelerated Hypofractionated Radiation Therapy for ElderlyFrail Bladder Cancer Patients Unfit for Surgery or Chemotherapy. Am J Clin Oncol.2019 Feb;42(2):179-183. doi: 10.1097/COC.0000000000000491. PubMed PMID: 30451730.11: Kaiser J, Li H, North SA, Leibowitz-Amit R, Seah JA, Morshed N, Chau C,Lee-Ying R, Heng DYC, Sridhar S, Crabb SJ, Alimohamed NS. The Prognostic Role ofthe Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy inPatients with Muscle-Invasive Bladder Cancer: A Retrospective,Multi-Institutional Study. Bladder Cancer. 2018 Apr 26;4(2):185-194. doi:10.3233/BLC-170133. PubMed PMID: 29732389; PubMed Central PMCID: PMC5929304.12: Motzer RJ, et al; CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi:10.1056/NEJMoa1712126. Epub 2018 Mar 21. PubMed PMID: 29562145; PubMed CentralPMCID: PMC5972549.13: Abu-Ghanem Y, Ramon J, Berger R, Kaver I, Fridman E, Leibowitz-Amit R, DotanZA. Positive surgical margin following radical nephrectomy is an independentpredictor of local recurrence and disease-specific survival. World J Surg Oncol.2017 Nov 2;15(1):193. doi: 10.1186/s12957-017-1257-6. PubMed PMID: 29096642;PubMed Central PMCID: PMC5668980.14: Mizrahi A, Barzilai A, Gur-Wahnon D, Ben-Dov IZ, Glassberg S, Meningher T,Elharar E, Masalha M, Jacob-Hirsch J, Tabibian-Keissar H, Barshack I, Roszik J,Leibowitz-Amit R, Sidi Y, Avni D. Alterations of microRNAs throughout themalignant evolution of cutaneous squamous cell carcinoma: the role of miR-497 inepithelial to mesenchymal transition of keratinocytes. Oncogene. 2018 Jan11;37(2):218-230. doi: 10.1038/onc.2017.315. Epub 2017 Sep 18. PubMed PMID:28925390.15: Petrylak DP, et al; RANGE study investigators. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma afterplatinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.Lancet. 2017 Nov 18;390(10109):2266-2277. doi: 10.1016/S0140-6736(17)32365-6.Epub 2017 Sep 12. PubMed PMID: 28916371.16: Saad A, Goldstein J, Lawrence YR, Spieler B, Leibowitz-Amit R, Berger R,Davidson T, Urban D, Tsang L, Alezra D, Weiss I, Symon Z. Classifying high-riskversus very high-risk prostate cancer: is it relevant to outcomes of conformalradiotherapy and androgen deprivation? Radiat Oncol. 2017 Jan 6;12(1):5. doi:10.1186/s13014-016-0743-2. PubMed PMID: 28061904; PubMed Central PMCID:PMC5216523.17: Leibowitz-Amit R, Israel A, Gal M, Atenafu EA, Symon Z, Portnoy O, Laufer M,Dotan Z, Ramon J, Avni D, Fridman E, Berger R. Association between the AbsoluteBaseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapyin Muscle-invasive Bladder Cancer. Clin Oncol (R Coll Radiol). 2016Dec;28(12):790-796. doi: 10.1016/j.clon.2016.07.007. Epub 2016 Aug 5. PubMedPMID: 27498850.18: Bonen H, Kol N, Shomron N, Leibowitz-Amit R, Quagliata L, Lorber T, Sidi Y,Avni D. Promoter-Associated RNAs Regulate HSPC152 Gene Expression in MalignantMelanoma. Noncoding RNA. 2016 Jun 30;2(3). pii: E7. doi: 10.3390/ncrna2030007.PubMed PMID: 29657265; PubMed Central PMCID: PMC5831909.19: Leibowitz-Amit R, Pintilie M, Khoja L, Azad AA, Berger R, Laird AD, Aftab DT,Chi KN, Joshua AM. Changes in plasma biomarkers following treatment withcabozantinib in metastatic castration-resistant prostate cancer: a post hocanalysis of an extension cohort of a phase II trial. J Transl Med. 2016 Jan13;14:12. doi: 10.1186/s12967-015-0747-y. PubMed PMID: 26762579; PubMed CentralPMCID: PMC4712499.20: Zehavi L, Schayek H, Jacob-Hirsch J, Sidi Y, Leibowitz-Amit R*, Avni D.MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 inmalignant melanoma. Mol Cancer. 2015 Mar 26;14:68. doi:10.1186/s12943-015-0338-9. PubMed PMID: 25889255; PubMed Central PMCID:PMC4392476.* Equal corresponding author21: Seah JA, Leibowitz-Amit R*, Atenafu EG, Alimohamed N, Knox JJ, Joshua AM,Sridhar SS. Neutrophil-Lymphocyte Ratio and Pathological Response to NeoadjuvantChemotherapy in Patients With Muscle-Invasive Bladder Cancer. Clin GenitourinCancer. 2015 Aug;13(4):e229-e233. doi: 10.1016/j.clgc.2015.02.001. Epub 2015 Feb7. PubMed PMID: 25777682. * equal contribution22: Keizman D, Rouvinov K, Sella A, Gottfried M, Maimon N, Kim JJ, EisenbergerMA, Sinibaldi V, Peer A, Carducci MA, Mermershtain W, Leibowitz-Amit R, WeitzenR, Berger R. Is there a "Trial Effect" on Outcome of Patients with MetastaticRenal Cell Carcinoma Treated with Sunitinib? Cancer Res Treat. 2016Jan;48(1):281-7. doi: 10.4143/crt.2014.289. Epub 2015 Mar 5. PubMed PMID:25761478; PubMed Central PMCID: PMC4720089.23: Leibowitz-Amit R, Khoja L, Tannock IF, Joshua AM. Choosing a better end pointfor trials of bone-protective agents. Ann Oncol. 2015 May;26(5):1032-3. doi:10.1093/annonc/mdv039. Epub 2015 Jan 28. PubMed PMID: 25632065.24: Leibowitz-Amit R, Templeton AJ, Alibhai SM, Knox JJ, Sridhar SS, Tannock IF,Joshua AM. Efficacy and toxicity of abiraterone and docetaxel in octogenarianswith metastatic castration-resistant prostate cancer. J Geriatr Oncol. 2015Jan;6(1):23-8. doi: 10.1016/j.jgo.2014.09.183. Epub 2014 Oct 7. PubMed PMID:25301537.25: Lerman G, Sharon M, Leibowitz-Amit R, Sidi Y, Avni D. The crosstalk betweenIL-22 signaling and miR-197 in human keratinocytes. PLoS One. 2014 Sep10;9(9):e107467. doi: 10.1371/journal.pone.0107467. eCollection 2014. PubMedPMID: 25208211; PubMed Central PMCID: PMC4160297.26: Azad AA, Leibowitz-Amit R*, Eigl BJ, Lester R, Wells JC, Murray RN,Kollmannsberger C, Heng DY, Joshua AM, Chi KN. A retrospective, Canadianmulti-center study examining the impact of prior response to abiraterone acetateon efficacy of docetaxel in metastatic castration-resistant prostate cancer.Prostate. 2014 Nov;74(15):1544-50. doi: 10.1002/pros.22872. Epub 2014 Aug 29.PubMed PMID: 25175831. * equal contribution27: Leibowitz-Amit R, Alimohamed N, Vera-Badillo FE, Seah JA, Templeton AJ, KnoxJJ, Tannock IF, Sridhar SS, Joshua AM. Retreatment of men with metastaticcastrate-resistant prostate cancer with abiraterone. Prostate. 2014Oct;74(14):1462-4. doi: 10.1002/pros.22861. Epub 2014 Aug 11. PubMed PMID:25111736.28: Leibowitz-Amit R, Seah JA, Atenafu EG, Templeton AJ, Vera-Badillo FE,Alimohamed N, Knox JJ, Tannock IF, Sridhar SS, Joshua AM. Abiraterone acetate inmetastatic castration-resistant prostate cancer: a retrospective review of thePrincess Margaret experience of (I) low dose abiraterone and (II) priorketoconazole. Eur J Cancer. 2014 Sep;50(14):2399-407. doi:10.1016/j.ejca.2014.06.004. Epub 2014 Jul 16. PubMed PMID: 25042152.29: Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-BadilloFE, Attard G, de Bono JS, Tannock IF, Amir E. Simple prognostic score formetastatic castration-resistant prostate cancer with incorporation ofneutrophil-to-lymphocyte ratio. Cancer. 2014 Nov 1;120(21):3346-52. doi:10.1002/cncr.28890. Epub 2014 Jul 3. PubMed PMID: 24995769.30: Leibowitz-Amit R, Mete O, Asa SL, Ezzat S, Joshua AM. Malignantpheochromocytoma secreting vasoactive intestinal peptide and response tosunitinib: a case report and literature review. Endocr Pract. 2014Aug;20(8):e145-50. doi: 10.4158/EP14093.CR. Erratum in: Endocr Pract. 2015Jan;21(1):94. Lebowitz-Amit, Raya [corrected to Leibowitz-Amit, Raya]. PubMedPMID: 24936559.31: Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A,Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognosticrole of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review andmeta-analysis. J Natl Cancer Inst. 2014 May 29;106(6):dju124. doi:10.1093/jnci/dju124. Print 2014 Jun. Review. PubMed PMID: 24875653.32: Azad AA, Eigl BJ, Leibowitz-Amit R, Lester R, Kollmannsberger C, Murray N,Clayton R, Heng DY, Joshua AM, Chi KN. Outcomes with abiraterone acetate inmetastatic castration-resistant prostate cancer patients who have poorperformance status. Eur Urol. 2015 Mar;67(3):441-7. doi:10.1016/j.eururo.2014.01.030. Epub 2014 Jan 31. PubMed PMID: 24508071.33: Leibowitz-Amit R, Templeton AJ, Omlin A, Pezaro C, Atenafu EG, Keizman D,Vera-Badillo F, Seah JA, Attard G, Knox JJ, Sridhar SS, Tannock IF, de Bono JS,Joshua AM. Clinical variables associated with PSA response to abiraterone acetatein patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2014Mar;25(3):657-62. doi: 10.1093/annonc/mdt581. Epub 2014 Jan 23. PubMed PMID:24458472; PubMed Central PMCID: PMC4433513.34: Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A,Leibowitz-Amit R, Berger R, Keizman D. Comparison of abiraterone acetate versusketoconazole in patients with metastatic castration resistant prostate cancerrefractory to docetaxel. Prostate. 2014 Apr;74(4):433-40. doi:10.1002/pros.22765. Epub 2013 Dec 11. PubMed PMID: 24338986; PubMed CentralPMCID: PMC4696030.35: Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, De Gouveia P,Leibowitz-Amit R, Knox JJ, Moore M, Sridhar SS, Joshua AM, Pond GR, Amir E,Tannock IF. Translating clinical trials to clinical practice: outcomes of menwith metastatic castration resistant prostate cancer treated with docetaxel andprednisone in and out of clinical trials. Ann Oncol. 2013 Dec;24(12):2972-7. doi:10.1093/annonc/mdt397. Epub 2013 Oct 14. PubMed PMID: 24126362.36: Leibowitz-Amit R, Joshua AM. The changing landscape in metastaticcastration-resistant prostate cancer. Curr Opin Support Palliat Care. 2013Sep;7(3):243-8. doi: 10.1097/SPC.0b013e328362ffef. Review. PubMed PMID: 23817317.37: Leibowitz-Amit R, Joshua AM. Targeting the androgen receptor in themanagement of castration-resistant prostate cancer: rationale, progress, andfuture directions. Curr Oncol. 2012 Dec;19(Suppl 3):S22-31. doi:10.3747/co.19.1281. PubMed PMID: 23355790; PubMed Central PMCID: PMC3553559.38: Leibowitz-Amit R, Sidi Y, Avni D. Aberrations in the micro-RNA biogenesismachinery and the emerging roles of micro-RNAs in the pathogenesis of cutaneousmalignant melanoma. Pigment Cell Melanoma Res. 2012 Nov;25(6):740-57. doi:10.1111/pcmr.12018. Review. PubMed PMID: 22958787.39: Zehavi L, Avraham R, Barzilai A, Bar-Ilan D, Navon R, Sidi Y, Avni D,Leibowitz-Amit R. Silencing of a large microRNA cluster on human chromosome 14q32in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor1 receptor. Mol Cancer. 2012 Jul 2;11:44. PubMed PMID: 22747855; PubMed CentralPMCID: PMC3444916.40: Leibowitz-Amit R, Tsarfaty G, Abargil Y, Yerushalmi GM, Horev J, Tsarfaty I.Mimp, a mitochondrial carrier homologue, inhibits Met-HGF/SF-induced scatteringand tumorigenicity by altering Met-HGF/SF signaling pathways. Cancer Res. 2006Sep 1;66(17):8687-97. PubMed PMID: 16951184.41: Yerushalmi GM, Leibowitz-Amit R*, Shaharabany M, Tsarfaty I. Met-HGF/SF signaltransduction induces mimp, a novel mitochondrial carrier homologue, which leadsto mitochondrial depolarization. Neoplasia. 2002 Nov-Dec;4(6):510-22. PubMedPMID: 12407445; PubMed Central PMCID: PMC1503665.* equal contribution42: Hauben E, Butovsky O, Nevo U, Yoles E, Moalem G, Agranov E, Mor F,Leibowitz-Amit R, Pevsner E, Akselrod S, Neeman M, Cohen IR, Schwartz M. Passiveor active immunization with myelin basic protein promotes recovery from spinalcord contusion. J Neurosci. 2000 Sep 1;20(17):6421-30. Erratum in: J Neurosci.2016 Feb 10;36(6):2075. PubMed PMID: 10964948; PubMed Central PMCID: PMC6772980.43: Moalem G, Yoles E, Leibowitz-Amit R, Muller-Gilor S, Mor F, Cohen IR,Schwartz M. Autoimmune T cells retard the loss of function in injured rat opticnerves. J Neuroimmunol. 2000 Jul 1;106(1-2):189-97. PubMed PMID: 10814797.44: Schwartz M, Moalem G, Leibowitz-Amit R, Cohen IR. Innate and adaptive immuneresponses can be beneficial for CNS repair. Trends Neurosci. 1999Jul;22(7):295-9. Review. PubMed PMID: 10370250.45: Moalem G, Leibowitz-Amit R*, Yoles E, Mor F, Cohen IR, Schwartz M. AutoimmuneT cells protect neurons from secondary degeneration after central nervous systemaxotomy. Nat Med. 1999 Jan;5(1):49-55. PubMed PMID: 9883839. * equal contribution.
bottom of page